us en false false Default

PPH

VanEck
Pharmaceutical ETF

As of March 31, 2025

Fund Details

Fund Ticker PPH
Intraday NAV (IIV) PPHIV
Index Ticker MVPPHTR
Total Net Assets ($M) 668.74
Options Available
Exchange Nasdaq
Inception Date 12/20/11

Fund Data

Number of Holdings 26
Currency USD
Price/Earnings Ratio* 26.10
Price/Book Ratio* 3.51
Weighted Avg. Market Cap ($M) $226,769
30-Day SEC Yield 2.10
NAV: 52 Week High/Low $99.41/$84.86
*30-Day SEC Yield is a standard yield calculation developed by the Securities and Exchange Commission that allows for fairer comparisons among funds. It is based on the most recent 30-day period. This yield figure reflects the interest earned during the period after deducting the fund's expenses for the period. It does not reflect the yield an investor would have received if they had held the fund over the last twelve months assuming the most recent NAV. Distributions may vary from time to time.

Fees and Expenses

Management Fee 0.35%
Other Expenses 0.01%
Acquired Fund Fees and Expenses --
Gross Expense Ratio 0.36%
Fee Waivers and
Expense Reimbursement		 --
Net Expense Ratio 0.36%

Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2026.

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Top 10 Holdings

Holding Name
Ticker
 % of Net Assets
Eli Lilly & Co
LLY US
 11.85
Johnson & Johnson
JNJ US
 6.64
Abbvie Inc
ABBV US
 6.63
Novartis Ag
NVS US
 5.14
Cencora Inc
COR US
 4.93
Astrazeneca Plc
AZN US
 4.87
Merck & Co Inc
MRK US
 4.81
Sanofi Sa/France
SNY US
 4.81
Mckesson Corp
MCK US
 4.73
Novo Nordisk A/S
NVO US
 4.65
Top 10 Total 59.06
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Performance History:

Average Annual Total Returns* (%)

Month End as of 03/31/25 1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) -2.71 5.58 5.58 2.39 6.54 12.90 4.61 9.40
PPH (Share Price) -2.69 5.62 5.62 2.40 6.51 12.92 4.60 9.48
MVPPHTR (Index) -2.75 5.46 5.46 1.99 6.13 12.52 4.41 9.22
Performance Differential (NAV - Index) 0.04 0.12 0.12 0.40 0.41 0.38 0.20 0.18
Quarter End as of 03/31/25 1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) -2.71 5.58 5.58 2.39 6.54 12.90 4.61 9.40
PPH (Share Price) -2.69 5.62 5.62 2.40 6.51 12.92 4.60 9.48
MVPPHTR (Index) -2.75 5.46 5.46 1.99 6.13 12.52 4.41 9.22
Performance Differential (NAV - Index) 0.04 0.12 0.12 0.40 0.41 0.38 0.20 0.18

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The Fund’s prospectus has not been submitted for approval to the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten / Autorité des Services et Marchés Financiers) and, accordingly, the shares may not be distributed by way of public offering in Belgium and may only be offered to a maximum of 99 investors or to institutional and professional investors (as defined in Article 5, §3 of the Law of July 20, 2004, and as extended by the provisions of the Belgian Royal Decree of September 26, 2006 . These materials may be distributed in Belgium only to such prospective investors for their personal use and may not be used for any other purpose or passed on to any other person in Belgium. Shares will only be offered to such qualifying prospective investors.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The "Net Asset Value" (NAV) of a Fund is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell shares at NAV.

PPH

VanEck
Pharmaceutical ETF

As of March 31, 2025

Top 10 Countries

Country % of Net Assets
United States 62.41
United Kingdom 13.91
Switzerland 5.14
France 4.81
Denmark 4.65
Japan 4.49
Israel 4.20
Other/Cash 0.40
Top 10 Total 100.00

Sector Weightings

Sector % of Net Assets
■ Health Care 99.6
■ Other/Cash 0.4
Created with Highcharts 9.3.3Chart context menu

Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Certain indices may take into account withholding taxes. Investors can not invest directly in the Index. Index returns assume that dividends have been reinvested.

An investment in the Fund may be subject to risks which include, among others, risks related to investing in the pharmaceutical industry, health care sector, equity securities, depositary receipts, special risk considerations of investing in United Kingdom and European issuers, foreign securities, foreign currency, small- and medium-capitalization companies, issuer-specific changes, market, operational, index tracking, authorized participant concentration, no guarantee of active trading market, trading issues, passive management, fund shares trading, premium/discount and liquidity of fund shares, non-diversified, and index-related concentration risks, all of which may adversely affect the Fund. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund's returns. Small- and medium-capitalization companies may be subject to elevated risks.

MVIS US Listed Pharmaceutical 25 Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Securities Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH, Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Pharmaceutical ETF is not sponsored, endorsed, sold or promoted by MarketVector Indexes GmbH and MarketVector Indexes GmbH makes no representation regarding the advisability of investing in the Fund.

Investing involves substantial risk and high volatility, including possible loss of principal.  An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contains this and other information, call 800.826.2333 or visit vaneck.com. Please read the prospectus and summary prospectus carefully before investing.

This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction.

Van Eck Securities Corporation, Distributor, a wholly-owned subsidiary of Van Eck Associates Corporation | 666 Third Avenue | New York, NY 10017 

FUND TICKER: PPH 800.826.2333 VANECK.COM